IRCT20200324046850N2 IRCT 2020-03-29 Abadan University of Medical Sciences Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms 2020-03-18 anticipated 62 Complete https://irct.ir/trial/46713 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: -. 2 COVID-19. Intervention 1: lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose + sofosbuvir (400 mg)- daclatasvir (60 mg) take one tablet daily until clinical symptoms improve. Intervention 2: Intervention group 2: lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose + ribavirin (200 mg) 6 tablets every 12 hours until clinical symptoms improve. Yes - There is a plan to make this available What will be shared: -All data can be shared after the participants in the study are unrecognizable. When: The data access period after printing the article To whom: -The data in this study will be available to researchers working at academic and scientific institutions, as well as the Food and Drug Administration. Conditions: - Any analysis can be done with the consent of the main researcher. Where to obtain: -s.mobarak@abadanums.ac.ir How to obtain: -The researcher or pharmaceutical company can send their request to the academic email after sending the documents to confirm their original identity. Comments: -